Side effects of pharmacotherapy on bone with long-acting gonadorelin agonist triptorelin for paraphilia.

Hoogeveen J, Van der Veer E

The journal of sexual medicine30 Oct 2007Cited by 9 (Europe PMC)

PMID17971105DOI10.1111/j.1743-6109.2007.00642.xPepBankPUB-17971105

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Gonadorelin (GnRH, LHRH) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Gonadorelin (GnRH, LHRH).

01HumanNot a test of Gonadorelin (GnRH, LHRH) aloneCase report or seriesEfficacy outcome
In a 35-year-old man with a paraphilia, long-acting triptorelin, a gonadorelin agonist, was followed by reduced preoccupation with sexuality.
In plain wordsIn one man with a paraphilia, the long-acting drug triptorelin was followed by less preoccupation with sexuality.
Peptide
Gonadorelin (GnRH, LHRH)
Outcome
DecreasePreoccupation with sexuality
Study
n = 1
Outcome group
Sexual function · Reproductive and sexual health
Source sentences
Summary
The desired result was reduced preoccupation with sexuality
1 context sentence(design, population, supporting numbers)
Summary · context
A 35-year-old man with a paraphilia was treated with long-acting gonadorelin.
In this study, Gonadorelin (GnRH, LHRH) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Gonadorelin (GnRH, LHRH).
Report a problemFND-1797110501
02HumanNot a test of Gonadorelin (GnRH, LHRH) aloneCase report or seriesSafety outcome
In a 35-year-old man with a paraphilia, long-acting triptorelin, a gonadorelin agonist, was followed by a serious amount of bone loss.
In plain wordsIn one man with a paraphilia, the long-acting drug triptorelin was followed by serious bone loss.
Peptide
Gonadorelin (GnRH, LHRH)
Outcome
DecreaseBone loss
Study
n = 1
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
there were various side effects including a serious amount of bone loss
1 context sentence(design, population, supporting numbers)
Summary · context
A 35-year-old man with a paraphilia was treated with long-acting gonadorelin.
In this study, Gonadorelin (GnRH, LHRH) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Gonadorelin (GnRH, LHRH).
Report a problemFND-1797110502

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 2
13 Oct 2026, 21:44 UTC
Study results updated
Version 1
13 Oct 2026, 16:31 UTC
First added · source update from Europe PMC